Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation

John G. Keilp, PhD; Sean P. Madden, MS; Julia E. Marver, PhD; Abigail Frawley, PhD; Ainsley K. Burke, PhD; Mohammad M. Herzallah, PhD; Mark Gluck, PhD; J. John Mann, MD; Michael F. Grunebaum, MD

J Clin Psychiatry 2021;82(6):21m13921

ABSTRACT

Objective: Subanesthetic ketamine rapidly reduces depressive symptoms and suicidal ideation in some depressed patients. Its effects on neurocognitive functioning in such individuals with significant suicidal ideation is not well understood, even though certain neurocognitive deficits are associated with suicide behavior beyond clinical symptoms.

Methods: In this study, depressed patients with clinically significant suicidal ideation (n = 78) underwent neuropsychological testing before and 1 day after double-blind treatment with intravenous ketamine (n = 39) or midazolam (n = 39). A subgroup randomized to midazolam whose ideation did not remit after initial infusion received open ketamine and additional neurocognitive testing a day after this treatment. The primary outcome was change in performance on this neurocognitive battery. The study was conducted between November 2012 and January 2017.

Results: Blinded ketamine produced rapid improvement in suicidal ideation and mood in comparison to midazolam, as we had reported previously. Ketamine, relative to midazolam, was also associated with specific improvement in reaction time (Choice RT) and interference processing/cognitive control (computerized Stroop task)—the latter a measure that has been associated with past suicide attempt in depression. In midazolam nonremitters later treated with open ketamine and retested, reaction time and interference processing/cognitive control also improved relative to both of their prior assessments. Neurocognitive improvement, however, was not correlated with changes in depression, suicidal thinking, or general mood.

Conclusions: Overall, ketamine was found to have a positive therapeutic effect on neurocognition 1 day after treatment on at least 1 measure associated with suicidal behavior in the context of depression. Results suggest additional independent therapeutic effects for ketamine in the treatment of depressed patients at risk for suicidal behavior.

Trial Registration: ClinicalTrials.gov identifier: NCT01700829

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (43)

Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. PubMed CrossRef
Sinyor M, Williams M, Belo S, et al. Ketamine augmentation for major depressive disorder and suicidal ideation: preliminary experience in an inpatient psychiatry setting. J Affect Disord. 2018;241:103–109. PubMed CrossRef
Ballard ED, Yarrington JS, Farmer CA, et al. Characterizing the course of suicidal ideation response to ketamine. J Affect Disord. 2018;241:86–93. PubMed CrossRef
Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry. 2020;54(1):29–45. PubMed CrossRef
Keilp JG, Gorlyn M, Russell M, et al. Neuropsychological function and suicidal behavior: attention control, memory and executive dysfunction in suicide attempt. Psychol Med. 2013;43(3):539–551. PubMed CrossRef
Keilp JG, Beers SR, Burke AK, et al. Neuropsychological deficits in past suicide attempters with varying levels of depression severity. Psychol Med. 2014;44(14):2965–2974. PubMed CrossRef
Richard-Devantoy S, Berlim MT, Jollant F. A meta-analysis of neuropsychological markers of vulnerability to suicidal behavior in mood disorders. Psychol Med. 2014;44(8):1663–1673. PubMed CrossRef
Passie T, Karst M, Wiese B, et al. Effects of different subanesthetic doses of S-ketamine on neuropsychology, psychopathology, and state of consciousness in man. Neuropsychobiology. 2005;51(4):226–233. PubMed CrossRef
Morgan CJ, Mofeez A, Brandner B, et al. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology. 2004;29(1):208–218. PubMed CrossRef
Honey RA, Turner DC, Honey GD, et al. Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology. 2003;28(11):2037–2044. PubMed CrossRef
Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199–214. PubMed CrossRef
Morgan CJ, Mofeez A, Brandner B, et al. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study. Psychopharmacology (Berl). 2004;172(3):298–308. PubMed
Morgan CJ, Rossell SL, Pepper F, et al. Semantic priming after ketamine acutely in healthy volunteers and following chronic self-administration in substance users. Biol Psychiatry. 2006;59(3):265–272. PubMed CrossRef
Hayley A, Green M, Downey L, et al. Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine. Psychopharmacology (Berl). 2018;235(4):1273–1282. PubMed CrossRef
Ke X, Ding Y, Xu K, et al. The profile of cognitive impairments in chronic ketamine users. Psychiatry Res. 2018;266:124–131. PubMed CrossRef
Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105(1):121–133. PubMed CrossRef
Permoda-Osip A, Kisielewski J, Bartkowska-Sniatkowska A, et al. Single ketamine infusion and neurocognitive performance in bipolar depression. Pharmacopsychiatry. 2015;48(2):78–79. PubMed
Murrough JW, Burdick KE, Levitch CF, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015;40(5):1084–1090. PubMed CrossRef
Zheng W, Zhou YL, Liu WJ, et al. Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. J Affect Disord. 2019;246:241–247. PubMed CrossRef
Romeo B, Choucha W, Fossati P, et al. Clinical and biological predictors of ketamine response in treatment-resistant major depression: review [in French]. Encephale. 2017;43(4):354–362. PubMed CrossRef
Keilp JG, Sackeim HA, Mann JJ. Correlates of trait impulsiveness in performance measures and neuropsychological tests. Psychiatry Res. 2005;135(3):191–201. PubMed CrossRef
Wechler D. Wechler Adult Intelligence Scale. 3rd ed. The Psychological Corporation; 1997.
Cornblatt BA, Risch NJ, Faris G, et al. The Continuous Performance Test, identical pairs version (CPT-IP), I: new findings about sustained attention in normal families. Psychiatry Res. 1988;26(2):223–238. PubMed CrossRef
MacLeod CM. Half a century of research on the Stroop effect: an integrative review. Psychol Bull. 1991;109(2):163–203. PubMed CrossRef
Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24(11):1019–1025. PubMed CrossRef
Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination. 3rd ed. AJA Associates; 1983.
Gorlyn M, Keilp J, Burke A, et al. Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs bupropion. Psychiatry Res. 2015;225(3):407–412. PubMed CrossRef
Kanto J, Allonen H. Pharmacokinetics and the sedative effect of midazolam. Int J Clin Pharmacol Ther Toxicol. 1983;21(9):460–463. PubMed
Crowe SF, Stranks EK. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Arch Clin Neuropsychol. 2018;33(7):901–911. PubMed CrossRef
Lister RG. The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev. 1985;9(1):87–94. PubMed CrossRef
Keilp JG, Madden SP, Gorlyn M, et al. The lack of meaningful association between depression severity measures and neurocognitive performance. J Affect Disord. 2018;241:164–172. PubMed CrossRef
Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964. PubMed CrossRef
Ardalan M, Rafati AH, Nyengaard JR, et al. Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus. Br J Pharmacol. 2017;174(6):483–492. PubMed CrossRef
Clarke M, Razmjou S, Prowse N, et al. Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes. Neuropharmacology. 2017;112(pt A):210–220. PubMed CrossRef
Dakwar E, Nunes EV, Hart CL, et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry. 2019;176(11):923–930. PubMed CrossRef
Dakwar E, Levin F, Hart CL, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177(2):125–133. PubMed CrossRef
Kaplan S, Berman MG. Directed attention as a common resource for executive functioning and self-regulation. Perspect Psychol Sci. 2010;5(1):43–57. PubMed CrossRef
Hofmann W, Freise M, Roefs A. Three ways to resist temptation: the independent contributions of executive attention, inhibitory control, and affect regulation to the impulse control of eating behavior. J Exp Soc Psychol. 2009;45(2):431–435. CrossRef
Kotabe HP, Hofmann W. On integrating the components of self-control. Perspect Psychol Sci. 2015;10(5):618–638. PubMed CrossRef
Venezia RG, Gorlyn M, Burke AK, et al. The impact of cognitive reserve on neurocognitive performance in major depressive disorder. Psychiatry Res. 2018;270:211–218. PubMed CrossRef
Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020;45(4):606–612. PubMed CrossRef
Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893–903. PubMed CrossRef
Morgan CJ, Monaghan L, Curran HV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction. 2004;99(11):1450–1461. PubMed CrossRef